Immutep Stock Forecast for 2023 - 2025 - 2030
Updated on 05/01/2024
Immutep Stock Forecast and Price Target
In recent months, two notable analysts have provided yearlong price targets for Immutep, with the average target coming in at $1.00. If it were to be achieved, this would result in a potential upside of approximately 138.1 percent from the most recent closing price in May, 2024. The high end is $1.10, and the low is $0.80. If you are interested in IMM stock, it is important to also consider its competitors.
138.10% Upside
Immutep Fair Value Forecast for 2023 - 2025 - 2030
Immutep's Price has grown In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $0.43 – an increase of 100.00%. For the next eight years, experts predict that Immutep's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
12
|
$274.49 | Buy/Sell | $205.51 | -25.99% |
| TLX Stock Forecast | Telix Pharmaceuticals | Buy |
6
|
$14.67 | Buy/Sell | $13.37 | -1.16% |
| NEU Stock Forecast | Neuren Pharmaceuticals | Buy |
11
|
$19.06 | Buy/Sell | $26.43 | 39.45% |
| PNV Stock Forecast | PolyNovo | Outperform |
8
|
$2.01 | Buy/Sell | $1.88 | 6.47% |
| CUV Stock Forecast | Clinuvel Pharmaceuticals | Buy |
16
|
$15.06 | Buy/Sell | $27.41 | 47.74% |
Immutep Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Immutep's Revenue has seen a drop from $13.74M to $3.51M – a 74.45% decrease. In the next year, analysts believe that Revenue will reach $8.27M – an increase of 135.61%. For the next seven years, experts predict that Immutep's Revenue will grow at a rate of 15190.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IMU Stock Forecast | Imugene | Buy |
4
|
$0.08 | Buy/Sell | $0.35 | 425.00% |
| OPT Stock Forecast | Opthea | Underperform |
10
|
$0.62 | Buy/Sell | $1.15 | 12.90% |
| MSB Stock Forecast | Mesoblast | Buy |
9
|
$1.10 | Buy/Sell | $0.69 | 0.00% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PYC Stock Forecast | PYC Therapeutics | Buy |
8
|
$0.10 | Buy/Sell | $0.30 | 260.00% |
| CGS Stock Forecast | Cogstate | Buy |
11
|
$1.40 | Buy/Sell | $1.85 | 28.57% |
| BOT Stock Forecast | Botanix Pharmaceuticals | - |
0
|
$0.19 | Buy/Sell | $0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DXB Stock Forecast | Dimerix |
0
|
$0.32 | Buy/Sell | $0.00 | 81.25% | |
| ACW Stock Forecast | Actinogen Medical |
5
|
$0.04 | Buy/Sell | $0.15 | -100.00% | |
| BIT Stock Forecast | Biotron | - |
0
|
$0.06 | Buy/Sell | $0.00 | -100.00% |
Immutep EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Immutep's EBITDA has grown, moving from $-13.12M to $-39.57M – an increase of 201.60%. In the next year, analysts predict that EBITDA will jump to $-47.05M – up 18.90% from the current level. In 2030, professionals predict that Immutep's EBITDA will decrease by 406.55%, to $121.30M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SPL Stock Forecast | Starpharma Holdings | - |
8
|
$0.12 | Buy/Sell | $0.95 | -100.00% |
| IVX Stock Forecast | Invion | - |
0
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
| PTX Stock Forecast | Prescient Therapeutics |
2
|
$0.05 | Buy/Sell | $0.20 | 180.00% |
Immutep EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Immutep's EBIT has seen an increase, rising from $-15.07M to $-41.43M. This represents a growth of 174.92%. Analysts predict that Immutep's EBIT will increase in the upcoming year, reaching $-42.96M. This would represent an increase of 3.69%. By 2030, professionals predict that Immutep's EBIT will decrease by 1987.98%, to $782.19M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CYP Stock Forecast | Cynata Therapeutics |
0
|
$0.23 | Buy/Sell | $1.24 | 439.13% | |
| 1AI Stock Forecast | Algorae Pharmaceuticals | - |
-4
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
| IMC Stock Forecast | Immuron | - |
0
|
$0.07 | Buy/Sell | $0.00 | -100.00% |
Immutep EPS Price Prediction Forecast for 2023 - 2025 - 2030
Immutep's EPS has grown In the last four years, rising from $-0.03 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $-0.03 – an increase of 100.00%. For the next eight years, experts predict that Immutep's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ATH Stock Forecast | Alterity Therapeutics | - |
0
|
$0.00 | Buy/Sell | $0.75 | 0.00% |
| GTG Stock Forecast | Genetic Technologies | - |
0
|
$0.12 | Buy/Sell | $1.00 | -100.00% |
| OSL Stock Forecast | OncoSil Medical | - |
0
|
$0.01 | Buy/Sell | $0.11 | -100.00% |
.jpg)